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We are reporting a case of a young woman with acute myelogenous leukemia status postallogeneic transplantation who developed
multiply recurrent chloromas occurring along peripheral nerves in the absence of bone marrow relapse, all treated with radiation
therapy. The patient is currently free of disease nearly four years after her ﬁrst posttransplant chloroma. The case presented
is unique for its isolated peripheral nervous system involvement, rare posttransplant occurrence, and indolent course without
marrow relapse despite multiple extramedullary recurrences.
1.Introduction
Chloroma (also known as granulocytic sarcoma or myeloid
sarcoma) is a rare, extramedullary tumor composed of
immature granulocytic cells. It was ﬁrst described in 1811
[1] and coined “chloroma” by King [2] in 1853 because
of its green color. Its relationship with leukemia was later
established in 1893 [3].
Chloromas are reported in 2.5%–9.1% [4–6]o fp a t i e n t s
with acute myeloid leukemia (AML) and occur concomi-
tantly, following, or rarely antedating the onset of leukemia
[7]. The presence of an extramedullary relapse of leukemia
is often associated with a poor prognosis [8]. Chloromas’
clinical manifestations are diverse given their various sites
of occurrence. Involvement of isolated peripheral nerves by
chloromas is exceedingly rare and is documented only in
limited reports preceding more widespread relapse in the
majority of cases [9–12].
2.CaseReport
In June 2004, a 21-year-old white woman presented with
spiking fevers, bruising, shortness of breath, and malaise.
Laboratory ﬁndings revealed a white blood cell count of
21,700/µL with 47% circulating blasts. Subsequent bone
marrow evaluation demonstrated AML with del(9q). Lum-
bar puncture was negative for cerebral spinal ﬂuid (CSF)
involvement. The patient underwent prompt treatment with
cytarabine(Ara-C)200mg/m2 continuousinfusionforseven
days and idarubicin 12mg/m2 daily for three days. Bone
marrow evaluation at day 14 revealed residual leukemia,
and repeat bone marrow evaluation three weeks later was
negative. The patient subsequently received consolidative
treatment with four cycles of high dose Ara-C.
While receiving the chemotherapy, the patient developed
pain in her left shoulder which radiated down the left arm
from the elbow into the ulnar two ﬁngers with numbness
in those digits. The pain progressed, and further work-up
was pursued including electromyography (EMG), which was
consistent with an ulnar neuropathy. The patient underwent
transposition of the ulnar nerve and carpal tunnel release
because of new slight thumb numbness. The patient’s symp-
toms progressed despite the procedure to include impaired
dorsiﬂexion of the left great toe, numbness of her right calf,
and numbness and weakness of the right thumb and index
ﬁnger. Ten months after her initial diagnosis, associated
fatigue prompted a repeat bone marrow evaluation, which
was consistent with relapsed AML. Magnetic resonance
imaging (MRI) of the brachial plexus and lumbar spine
revealed bilateral brachial plexus involvement by a presumed2 Advances in Hematology
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Figure 1: Recurrent neurotropic chloroma of the right ulnar nerve on (a) pretreatment Positron Emission Tomography (PET) outlined
in red demonstrating resolution (b) of hypermetabolic activity after treatment to 24Gy to (c) the ﬁeld outlined in red. Biopsy proven
recurrent neurotropic chloroma on high power view with Heamtoxylin-Eosin staining (d) along the right psoas muscle outlined in red on
(e) pretreatment PET demonstrating resolution (f) of hypermetabolic activity after treatment to 24Gy to (g) the ﬁeld outlined in red.
chloroma and leukemic inﬁltration of the left and right
lumbosacral plexus.
The patient initiated treatment with mitoxantrone and
etoposide. Repeat bone marrow evaluation was negative and
repeat MRIs of the brachial plexus and lumbar spine demon-
strated resolution of the leukemic involvement. While post-
treatment biopsy of the chloroma sites was not performed,
it was felt that based on the available imaging, clinical
improvement, and bone marrow aspiration results, that the
patient had attained a complete response to treatment. The
patient underwent an unrelated donor-matched allogeneic
bonemarrowtransplant.Theconditioningregimenincluded
total body irradiation (TBI) to 1375cGy in 11 fractions
administered three times daily with a consolidative boost to
the left brachial plexus to 600cGy in four daily fractions.
The boost was added because residual microscopic disease
could not be ruled out. Graft versus host disease (GVHD)
prophylaxis included tacrolimus plus methotrexate.
Repeat bone marrow aspiration posttransplant demon-
strated cytogenetic remission with full donor chimerism
and normal karyotype. The patient completed ﬁve monthly
doses of intrathecal Ara-C (70mg) as central nervous system
(CNS) prophylaxis. Cytopathology on all the CSF samples
was negative for malignancy. The patient’s posttransplant
course was complicated by hepatic fungal infections, GVHD,
involving the upper gastrointestinal tract and liver, and
renal insuﬃciency resulting in a very slow but physically
remarkable recovery to eventually include triathlon training.
While on immune suppression including tacrolimus and
prednisone, the patient developed leukemia cutis of the
right chest that resolved completely with the tapering of
immunosuppressivemedications.Abonemarrowevaluation
atthetimeoftheskinbiopsyrevealedanormalkaryotype,all
donor by diagnostic molecular pathology.
Approximately one year posttransplant, the patient
developed progressive left intrinsic hand weakness with an
associated palpable mass in her left upper extremity. An
MRI study was consistent with a chloroma of the biceps
brachi along the course of the musculocutaneous nerve. Fine
needle aspiration of the mass was consistent with leukemic
inﬁltration; CSF analysis and bone marrow aspiration at
the time of the peripheral nerve biopsy were negative for
leukemic involvement, and polymorphism analysis with
DNA primers demonstrated complete donor engraftment.
The patient received a course of radiation therapy to
3000cGy in 15 fractions to the mass, with complete clinical
resolution of the lesion by treatment completion.
Sevenmonthsaftercompletionofthepatient’slastcourse
of radiation, she developed new right arm and leg pain.
Work-up including MRIs demonstrated three presumed
chloromas near the right elbow (ulnar nerve), right upper
deltoid (axillary nerve), and right psoas region (lumbar
plexus). Biopsy of the right psoas lesion was consistent with
chloroma (Figure 1); CSF analysis and bone marrow biopsy
were negative and polymorphism analysis did not detect
any host cells. The patient underwent her third course of
radiation to the right elbow, right deltoid region, and right
paraspinal psoas mass, each to 2400cGy in 12 fractions.Advances in Hematology 3
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Figure 2: Recurrent neurotropic chloroma of the right femoral nerve outlined in red on (a) pretreatment Positron Emission Tomography
(PET) and (b) coronal Computerized Tomography (CT) imaging with the (c) CT-based treatment ﬁeld outlined in red.
All sites demonstrated a clinical and radiographic response
(Figure 1) on followup. Three months after completion of
treatment, the patient developed new pain in her left ﬁrst
and second toes. Imaging was consistent with a left peroneal
nerve chloroma for which she received 2400cGy in 12
fractions.
The patient had been completely tapered oﬀ immuno-
suppression and was doing well on no further therapy
until 14 months later, when she palpated a new mass in
her left forearm, which was biopsied and consistent with
a leukemic inﬁltrate. Further work-up did not reveal any
systemic disease with bone marrow evaluation showing full
donor chimerism and no CSF involvement. The patient
was neurologically asymptomatic; however, neurological
examination was consistent with median nerve involvement.
A course of 2400cGy in 12 fractions to the left forearm
was initiated with clinical resolution. Despite the patients
multiple recurrences and courses of radiation, she remained
in excellent physical condition with continued participation
in triathlons and road races.
Despite receiving a low dose donor lymphocyte infusion
of 1 × 105 CD3+ cells/kg several months before, the
patient developed right lower extremity weakness along the
femoral distribution approximately one year after her last
radiation treatment. MRI, computerized tomography (CT),
and positron emission tomography (PET) were consistent
with a right femoral nerve chloroma extending into the
right inguinal canal (Figure 2). The patient received another
course of 2400cGy in 12 fractions with a cone down to avoid
overlap with the prior radiation ﬁeld (right psoas chloroma).
Clinical improvement was observed during the course of
treatmentwithoutanyassociatedtreatmenttoxicities.Repeat
MRI one month after treatment demonstrated complete
resolution.
Since completion of her last course of radiation therapy,
she has received no further therapy and has not shown any
evidence of recurrence of chloroma or leukemia; the patient
plans to resume her triathlon training.
3. Discussion
The most common locations of chloromas are skin, soft
tissue, bone, periosteum, and lymph nodes [8]. Central
nervous system (CNS) involvement is rare but has been
describedinnumerouscasereports[13–15].Bycontrast,iso-
lated peripheral nervous system (PNS) involvement without
epidural or leptomeningeal involvement is exceedingly rare.
An extensive review of the literature documents only four
suchcases[9–12].Inthreeofthecases,thepatient’sleukemia
subsequently recurred within a short interval either in the
CSF or marrow resulting in death; autopsy in the fourth case
demonstrated leukemic cells in the eyes but none in the CSF
or marrow.
The incidence of chloromas developing after allogeneic
transplantation has been reported in 0.2–1.3% of patients
undergoing transplantation with overall poor survival [16,
17]. Interestingly, in these two retrospective series a large
portion (48%) of chloromas occurred in the CNS struc-
tures and ovaries suggesting that chloromas might arise
in sanctuary sites where leukemic cells survive treatment
with chemoradiotherapy. The management of chloromas
after allogeneic transplantation is controversial. Aggressive
treatment with a second transplant is an option; however,
its eﬃcacy and safety is not established. Donor lymphocyte
infusion has also been attempted with clinical promise in a
select few cases [18]. Local therapy with radiation has been
utilized for palliation as well [17].
In the current case, involvement of the PNS pre- and
posttransplant suggests that peripheral nerves serve as a
sanctuary site. Leukemic cells in CNS structures and the
testes, which have inherent barriers [19, 20], are known
to escape systemic therapy. The existence of a blood-nerve
barrier could explain how relapse of acute leukemia might
originatewithleukemiccellsthathavepersistedinperipheral
nerves [21]. Theadministration of intrathecalchemotherapy
and the use of a testis boost for males during TBI can
overcome these barriers; however, no such method exists for
bypassing the blood-nerve barrier. It is therefore surprising
that more relapses do not occur in the PNS.
Chloromas following transplantation have convention-
ally been considered the ﬁrst manifestation of relapsed sys-
temic disease. However, rare isolated extramedullary relapses
ofleukemiawithoutconcomitantinvolvementofthemarrow
after allogenic transplantation have been described [22]. In
our patient, the selective involvement of extramedullary sites
might be attributable to a diﬀerential favorable graft versus
leukemia(GVL)eﬀectonthemarrowascomparedwithPNS.
This has resulted in excellent disease control with radiation4 Advances in Hematology
therapy alone. The unusually long survival, indolent course,
and absence of marrow relapse in this patient, despite
repeated chloromas, have been described previously in rare
cases posttransplant [23]. Notable in our patient was the
response of the leukemia cutis to withdrawal of immune
suppression,suggestingthatGVLwasadequatetocontrolthe
disease in the skin, a nonprivileged organ site.
Chloromas’ rare incidence, their often misdiagnosis [24],
and variable locations have resulted in limited clinical expe-
rience,andhenceinalackofconsensustreatmentguidelines.
The role of radiation in their management has typically
been palliative as low doses have resulted in excellent disease
control and symptom relief. In contrast to older studies that
support the use of at least 3000cGy, our experience with
this case and others suggests that 2400cGy is adequate [25].
Furthermore, despite having undergone TBI and multiple
courses of low-dose radiation, this patient’s treatment-
relatedtoxicityhasbeenminimal,suggestingthatinthiscase,
carefully planned reirradiation was safe. The applicability of
this type of regimen to similar presentations needs to be
considered on a case-by-case basis as all re-irradiation cases
requirecarefulscrutiny.Whilethemajorityofchloromaswill
lead to systemic relapse warranting systemic therapy, iso-
lated, indolent extramedullary recurrences might represent
a growing minority as allogeneic transplantation continues
to improve. Such isolated recurrences may beneﬁt from
radiation therapy.
In conclusion, we believe that this case is an important
contribution to our limited understanding of chloromas by
providing evidence that peripheral nerves can serve as a
sanctuary site for leukemic cells and an origin of chloromas.
This challenges the belief that chloromas always precede
systemic relapse and suggests an evolving role for radiation
therapy in the management of chloromas beyond palliation.
Further, more comprehensive studies of chloromas are
warranted to determine optimal management.
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